Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
VITRASE is an ovine-derived hyaluronidase injection approved in 2004 as a spreading agent and adjuvant to other injected drugs. It enzymatically degrades hyaluronic acid in subcutaneous and submucosal tissues, facilitating diffusion of co-administered medications and fluids. The product is used to enhance the efficacy and distribution of local anesthetics, antibiotics, and other parenteral agents.
With LOE approaching, the brand team is likely consolidating to defend core franchise against generics and alternative spreading agents; expect reduced headcount and shift to niche indication focus.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment
Evaluation of Vitrase as a Spreading Agent
Evaluation of Vitrase as an Adjuvant to Increase Absorption and Dispersion of Other Injected Anesthetics
Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)
Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)
Worked on VITRASE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bausch + Lomb is hiring 2 roles related to this product
VITRASE offers limited career expansion opportunities given zero linked job postings and LOE-approaching lifecycle stage. Roles focus on defensive market strategies and supply/reimbursement optimization rather than growth or innovation.